Compare Cassava Sciences Inc (FLNA) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs AT&T Inc. — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while AT&T Inc. trades at $22 (market cap $148.90B). The key difference: AT&T Inc. is far larger — about 2802× Cassava Sciences Inc's market cap, and AT&T Inc. pays a 5.18% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | T | |
|---|---|---|
Market Cap | $53.14M | $148.90B |
Sector | Health | Media |
52-Week High | $4.64 | $29.62 |
52-Week Low | $1.09 | $20.49 |
Enterprise Value | -$33.43M | $294.25B |
Dividend Yield | — | 5.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
AT&T (T) trades at $21.94, up 3.03% with strong fundamentals including a low P/E of 7.22 and robust cash flow generation of $15.12B in 2025. The stock shows bearish technical signals despite beating earnings estimates for three consecutive quarters. Recent news highlights competitive threats from SpaceX's Starlink, contributing to the stock trading near its 52-week low with a 5.3% dividend yield.
The investment case balances attractive valuation and dividend income against significant competitive risks. While analyst consensus targets $26.18 (19% upside), immediate headwinds from satellite competition and bearish technicals suggest cautious near-term positioning. Long-term investors may find value if AT&T successfully navigates industry disruption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
